3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
13
Urinary Bladder Neoplasms
12
Neoplasms
10
Carcinoma, Renal Cell
9
Ovarian Neoplasms
7
Carcinoma, Transitional Cell
7
Neoplasm Metastasis
6
Pancreatic Neoplasms
5
Breast Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
4
Carcinoma, Merkel Cell
4
Triple Negative Breast Neoplasms
3
Recurrence
3
Lymphoma
3
Lung Neoplasms
3
Fallopian Tube Neoplasms
3
Colorectal Neoplasms
3
Stomach Neoplasms
2
Prostatic Neoplasms
2
Melanoma
2
Leukemia, Myeloid, Acute
2
Kidney Neoplasms
2
Kidney Diseases
2
Carcinoma, Ovarian Epithelial
2
Carcinoma, Hepatocellular
2
Urothelial Cancer
1
Urologic Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Turcot syndrome
1
Interventions
Trastuzumab
3
Sugammadex
2
Neostigmine
2
Cisplatin
2
valrubicin
1
tucatinib
1
pembrolizumab
1
niraparib
1
enfortumab vedotin
1
avelumab
1
atezolizumab
1
Surveys and Questionnaires
1
Sunitinib
1
Standard of Care
1
Rocuronium
1
Pemetrexed
1
Paclitaxel
1
Nephroureterectomy
1
Neoadjuvant Therapy
1
Mitomycin
1
Lymph Node Excision
1
Glycopyrrolate
1
Gemcitabine
1
GSK-3326595
1
Fulvestrant
1
Docetaxel
1
Cetuximab
1
Afatinib
1
Administration, Intravesical
1
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Urologic Neoplasms
×
avelumab
×
Clear all
NCT02603432
2024-03-27
JAVELIN Bladder 100
Pfizer
Phase 3
Completed
700 enrolled
35 charts
1 FDA